首页> 外文期刊>International Journal of Pharmaceutics >In vitro controlled release of antihypertensive drugs intercalated into unmodified SBA-15 and MgO modified SBA-15 matrices
【24h】

In vitro controlled release of antihypertensive drugs intercalated into unmodified SBA-15 and MgO modified SBA-15 matrices

机译:嵌入到未修饰的SBA-15和MgO修饰的SBA-15基质中的降压药物的体外控制释放

获取原文
获取原文并翻译 | 示例
           

摘要

The use of nanotechnology in medicine and more specifically in drug delivery systems is set to spread rapidly. In order to broaden the range of matrices and implicitly to develop the class of drug delivery systems based on diffusion mechanism, in this study the starting materials, SBA-15 powder matrices, were engineered by MgO modification for antihypertensive drugs intercalation. Captopril and aliskiren were used as drug models. All powders, unmodified and MgO-modified silica matrices, and their corresponding drug-loaded samples were characterized by X-ray diffraction, N 2 adsorption and desorption, FTIR spectroscopy and scanning electron microscopy. The studied drug carriers were tested in the controlled drug release process and the influence of the silica pore morphology and geometry on drug release profiles was extensively studied. In order to analyze the data obtained from the in vitro release studies and to evaluate the kinetic release mechanism, the Korsmeyer and Peppas equation was used. The obtained drug delivery system based on MgO-SBA-15 matrix exhibits exciting structural features and is therefore promising for its use as antihypertensive drug delivery system, having potential therapeutic benefits resulting in safe and effective management of captopril and aliskiren adsorption and in vitro release.
机译:纳米技术在医学中,尤其是在药物输送系统中的应用势必迅速普及。为了拓宽基质的范围并隐含地开发基于扩散机理的药物递送系统,在本研究中,对原料SBA-15粉末基质进行了MgO修饰,以制备降压药物。卡托普利和阿利吉仑被用作药物模型。通过X射线衍射,N 2吸附和解吸,FTIR光谱和扫描电子显微镜对所有粉末,未改性和MgO改性的二氧化硅基质及其相应的载药样品进行了表征。在受控药物释放过程中测试了所研究的药物载体,并广泛研究了二氧化硅孔的形态和几何形状对药物释放曲线的影响。为了分析从体外释放研究中获得的数据并评估动力学释放机理,使用了Korsmeyer和Peppas方程。所获得的基于MgO-SBA-15基质的药物递送系统表现出令人兴奋的结构特征,因此有望将其用作降压药物递送系统,其具有潜在的治疗益处,从而导致安全有效地管理卡托普利和阿利吉仑的吸收以及体外释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号